45
BioTOPics 46 | September 2013
BioTOP-Report
Evestra GmbH
Evestra GmbH, founded in July 2008, is a
fully owned subsidiary of Evestra Inc. locat-
ed in San Antonio Texas. Evestra GmbH
serves as the development and commercial-
ization center for Europe and ROW. Evestra’s
mission is to develop and commercialize
steroid-based female healthcare products.
The development strategy of the company
includes product ideas with known com-
pounds as well as New Chemical Entities.
Evestra is conducting research and product
development in a number of in-demand, but
as yet unmet, medical need areas of wom-
en’s health such as hormonal-dependent
breast cancer and endometriosis. The com-
pany is also pursuing different projects in
fertility control, e.g. a new estrogen for oral
contraception, with superior pharmacologi-
cal properties compared to the standard
drug ethinyl estradiol.
Several patents on new composition of mat-
ter, new technical processes and use patents
have been filed during the last years and
support the strong intellectually property
position. Evestra is concentrating on R&D
and will seek more partners for commercial-
ization.
More detailed information can be found on
our website.
Address
Evestra GmbH
Britzer Straße 26
12439 Berlin · Germany
EU Contact
Prof. Klaus Nickisch · Managing Director
Phone +49 30 66509642
knickisch@evestra.com
www.evestra.com
LGC Genomics
LGC Genomics (www.lgcgenomics.com) is the
genomics division of the international sci-
ence-based LGC Group.
LGC Genomics merged 2011 with KBiosci-
ence, a UK-based technology company provid-
ing its own range of SNP genotyping chemis-
try and novel instrumentation to the life sci-
ence research and quality control communi-
ties. Now we provide a full range of high qual-
ity genomics products, services and solutions
including sample preparation, nucleic acid
extraction, DNA sequencing, genotyping and
biobanking. LGC Genomics operates from
three laboratory centers in Germany, USA and
United Kingdom.
The portfolio includes:
k
Genotyping services, assays and
reagents
k
Sanger and NextGen sequencing ser-
vices on Roche 454 & Illumina HiSeq and
MiSeq platforms
k
DNA and RNA extraction products and
services
k
DNA / RNA biobanking
k
Storage
k
Retrieval and analysis services
k
Reagents and consumables for molecular
biology
k
Laboratory instrumentation
k
Plate sealers
k
Liquid handling robots
k
High-throughput PCR thermal cyclers
k
Plate readers
Address
LGC Genomics GmbH
Ostendstrasse 25 · TGS Haus 8
12459 Berlin · Germany
Phone +49 30 53042200
info@lgcgenomics.com
www.lgcgenomics.com
©L
GC Limited, 2013. All rights r
eserved.
46
BioTOPics 46 | September 2013
BioTOP-Report
MOLOGEN AG
MOLOGEN AG is an innovative biotechnol-
ogy company with focus on cancer immuno
therapies. Our drug candidates utilize vari-
ous therapeutic approaches to fight severe
cancer diseases.
Our lead product is MGN1703 – a safe and
well tolerated DNA immuno modulator. It
has shown high efficacy in a double-blind,
placebo-controlled phase II trial in metastat-
ic colorectal cancer and is ready to enter
phase III. The immune activation is mediat-
ed through binding at the Toll-like receptor 9
in certain immune cells. The strong and
broad activation enables the patients’
immune system to overcome the tolerance
against the cancer disease. Due to this mode
of action MGN1703 can be used to treat
several solid cancer diseases. Next target
will be lung cancer.
Second lead product is MGN1601, our
cell-based cancer vaccine. Through the use
of living human renal cancer cells we pres-
ent a full set of tumor-associated antigens
(TAA) to the immune system with the aim to
induce a strong adaptive immune response
against these TAAs. MGN1601 underwent
successfully a phase I/II trial in metastatic
renal cancer.
Our attractive product pipeline also com-
prises DNA vaccines and further cancer
immuno therapies. The drug candidates are
based on our proprietary platform technolo-
gies. We are open for partnering and collab-
orations.
Our research for you – for innovative
medicines that are highly effective and well
tolerated.
Contact
MOLOGEN AG
Fabeckstraße 30
14195 Berlin · Germany
Phone +49 30 841788 0
Fax
+49 30 841788 50
info@mologen.com · www.mologen.com
Predemtec GmbH
Predemtec GmbH is focussed on research,
development, manufacture and marketing
of novel Immunoassay PredemtecDX to
assess dementia and dementia related risk
factors before first symptoms appear. Pre-
demtec has developed a reliable blood test
for early and reliable diagnosis of various
dementia-related disorders by analyzing a
cluster of specific biomarkers. Controlled
clinical tests indicate high specifity and reli-
ability of our PredemtecDX. Prophylaxis and
therapeutic interventions will be more effi-
cient, when administered as early as possi-
ble, ideally before clinical symptoms show.
PredemtecDX will enable a major progress in
this field.
Predemtec GmbH cooperates with the Insti-
tute of Immunology at the Kiel University
and various geriatric institutions in Germany
and Switzerland. As a member of the diag-
nostic network, Predemtec offers services
for early dementia diagnosis to laboratories,
hospitals and clinics.
Address
Predemtec GmbH
Neuendorfstrasse 20a/c
16761 Hennigsdorf
Contact
Dr. Annegret Feuerhelm-Heidl
Geschäftsführerin
Telefon +49 3302 2021600
Mobil +49 170 314145 9
info@predemtecDX.com
www.predemtecDX.com